Press Releases

Date Title and Summary
Toggle Summary Accuray Reports Fourth Quarter and Fiscal 2018 Financial Results
SUNNYVALE, Calif. , Aug. 16, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2018 . Q4 Fiscal 2018 and Recent Operating Highlights Gross orders increased 12 percent to $96.4 million Revenue increased to
Toggle Summary Addenbrooke's Hospital is First in the UK to Treat Cancer Patients with Accuray Radixact® System
Internationally Renowned Centre in Cambridge, England is First NHS Hospital to Install the Innovative Radiation Therapy System SUNNYVALE, Calif. , July 25, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today that the Addenbrooke's Hospital clinical team has treated the first
Toggle Summary Joseph E. Whitters Appointed to Accuray Board of Directors
SUNNYVALE, Calif. , July 19, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) announced today the appointment of Joseph E. Whitters to the company's Board of Directors, effective as of July 16, 2018 . In addition, he will serve on the Board's Audit Committee. With Mr.
Toggle Summary Accuray To Report Fiscal 2018 Fourth Quarter And Full Year Financial Results On August 16, 2018
SUNNYVALE, Calif. , July 19, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2018 ended June 30, 2018 on Thursday, August 16, 2018 after the market close. Management will host a conference call to review the fourth quarter results
Toggle Summary Accuray Receives AERB Approval for Sale and Supply of its Radixact® X9 System in India
SUNNYVALE, Calif. , June 21, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Company has received an Atomic Energy Regulatory Board (AERB) Type Approval for its Radixact ® X9 System in India . The AERB Type Approval indicates the device conforms to established
Toggle Summary New Studies Show the Accuray TomoTherapy® System Provides Greater Precision, Excellent Clinical Outcomes in Patients Undergoing Total Body Irradiation
SUNNYVALE, Calif. , May 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy ® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients
Toggle Summary Accuray CyberKnife® Customer Achieves Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study
- Results Demonstrate Exceptional Treatment Plan Quality Achievable with Accuray Treatment Planning Software (TPS) - Renowned Clinical Trials Group TROG Cancer Research and ProKnow Partnered to Host Study SUNNYVALE, Calif. , May 22, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY)
Toggle Summary Mercy Advances Cancer Care in Missouri with Multi-System, Multi-Hospital Agreement for Accuray Radiation Therapy Systems
- One-of-a-kind Accuray Radixact® and CyberKnife® Systems Offer Technological Innovations Designed to Deliver Unique Patient Benefits - Mercy is First in Missouri to Acquire the Radixact and CyberKnife M6™ Systems SUNNYVALE, Calif. , May 9, 2018 /PRNewswire/ --  Accuray Incorporated (Nasdaq: ARAY)
Toggle Summary Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules
SUNNYVALE, Calif. , May 4, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Patrick Spine , the company's new Senior Vice President, Human Resources.  As a material inducement to Mr.
Toggle Summary Accuray Reports Third Fiscal Quarter Results
SUNNYVALE, Calif. , April 30, 2018 /PRNewswire/ --  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third fiscal quarter ended March 31, 2018 . Fiscal Third Quarter Highlights Revenue increased 3 percent year over year to $99.8 million driven by service revenue growth